TrialThe Lancet. Respiratory medicine2022

Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR): a phase 3, randomised, placebo-controlled trial.

Zelalem Temesgen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.